Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI.
Marcus LindArndís Finna ÓlafsdóttirIrl B HirschJan BolinderSofia DahlqvistAldina PivodicJarl HellmanMagnus WijkmanErik SchwarczHenrik AlbrektssonTim HeiseWilliam H PolonskyPublished in: Diabetes care (2020)
The SILVER study supports beneficial long-term effects from CGM on HbA1c, hypoglycemia, treatment satisfaction, well-being, and hypoglycemic confidence in people with T1D managed with MDI.